TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

作者：N. Gangat, Momna Warraich, Sudhesh Kumar, Mahnoor Fatima, Kristen B. McCullough, K. Begna, A. Al-Kali, M. Patnaik, William J. Hogan, A. Mangaonkar, Antoine N. Saliba, M. Torghabeh, H. Alkhateeb, M. Shah, James M. Foran, T. Badar, Jeanne M Palmer, C. A. Yi, Animesh Pardanani, A. Tefferi · 发表于：American journal of hematology/oncology · 年份：2026 · DOI：10.1002/ajh.70248 · 被引用次数：1 · 研究领域：Medicine

Survival outcome among 82 Mayo Clinic patients with blast/accelerated phase myeloproliferative neoplasm (MPN-BP/AP).